These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30022801)

  • 21. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.
    Duthoit G; Silvain J; Marijon E; Ducrocq G; Lepillier A; Frere C; Dimby SF; Popovic B; Lellouche N; Martin-Toutain I; Spaulding C; Brochet E; Attias D; Mansourati J; Lorgis L; Klug D; Zannad N; Hauguel-Moreau M; Braik N; Deltour S; Ceccaldi A; Wang H; Hammoudi N; Brugier D; Vicaut E; Juliard JM; Montalescot G
    Circ Cardiovasc Interv; 2020 Jul; 13(7):e008481. PubMed ID: 32674675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patent foramen ovale and cryptogenic stroke: a matter of age?
    Handke M; Harloff A; Bode C; Geibel A
    Semin Thromb Hemost; 2009 Jul; 35(5):505-14. PubMed ID: 19739041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of cardioembolic stroke associated with patent foramen ovale.
    Mac Grory B; Ohman EM; Feng W; Xian Y; Yaghi S; Kamel H; Reznik ME
    BMJ; 2022 Feb; 376():e063161. PubMed ID: 35140114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
    Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
    Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
    Nasir UB; Qureshi WT; Jogu H; Wolfe E; Dutta A; Majeed CN; Tan WA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):187-193. PubMed ID: 30905408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insertable cardiac monitor detection of silent atrial fibrillation in candidates for percutaneous patent foramen ovale closure.
    Scacciatella P; Jorfida M; Biava LM; Meynet I; Zema D; D'Ascenzo F; Pristipino C; Cerrato P; Giustetto C; Gaita F
    J Cardiovasc Med (Hagerstown); 2019 May; 20(5):290-296. PubMed ID: 30921267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Important Changes for Practicing Physicians in the Focused Atrial Fibrillation Guideline Update.
    Link MS
    Circulation; 2020 Dec; 142(25):2399-2401. PubMed ID: 30704308
    [No Abstract]   [Full Text] [Related]  

  • 30. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patent foramen ovale.
    Alakbarzade V; Keteepe-Arachi T; Karsan N; Ray R; Pereira AC
    Pract Neurol; 2020 May; 20(3):225-233. PubMed ID: 32299831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke Prevention in Atrial Fibrillation: Looking Forward.
    Katsanos AH; Kamel H; Healey JS; Hart RG
    Circulation; 2020 Dec; 142(24):2371-2388. PubMed ID: 33315494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice.
    Sabir IN; Matthews GD; Huang CL
    Postgrad Med J; 2013 Jun; 89(1052):346-51. PubMed ID: 23404744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale.
    Danese A; Stegagno C; Tomelleri G; Piccoli A; Turri G; Carletti M; Variola A; Anselmi M; Mazzucco S; Ferrara A; Bovi P; Micheletti N; Cappellari M; Monaco S; Vassanelli C; Ribichini F;
    Acta Cardiol; 2017 Aug; 72(4):410-418. PubMed ID: 28705105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.
    Zhang XL; Kang LN; Wang L; Xu B
    BMC Cardiovasc Disord; 2018 Mar; 18(1):45. PubMed ID: 29499641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "One-stop shop": safety and efficacy of combining atrial septal defect occlusion and left atrial appendage closure for patients with atrial septal defect and atrial fibrillation.
    Zhang ZH; Yao Q; Huang HY; Zhu P; Xu X; Song ZY; Li HK
    BMC Cardiovasc Disord; 2020 Oct; 20(1):444. PubMed ID: 33045999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.